18th Annual CME Symposium
This advanced CME activity will provide participants with state-of-the-art information and practical guidance from internationally recognized experts on progress in managing HIV and viral hepatitis, including drug development and treatment, management of important comorbidities, and drug-drug interactions. The discussions at this meeting will allow clinicians to provide the highest quality of care in a variety of practice settings.
The primary goals of this activity are to increase each attendee’s competence to:
- Identify new antiretroviral drugs and drug combinations while exploring answers to uncertainties in treatment strategies
- Determine optimal approaches to diagnosis and treatment of important co-morbidities in patients with HIV infection, such as tuberculosis, malignancies and sexually transmitted infections
- Detail current and developing treatment options for managing patients with viral hepatitis and its complications, including in special populations
- Examine advances as well as controversies related to the transplantation of infected organs
- Evaluate approaches and expert strategies geared toward preventing care provider burnout
- Detail the impact of COVID-19 on HIV treatment and efforts to end this pandemic as well as the global epidemic of HIV
- Identify HIV medication-related adverse drug reactions and offer strategies on how to best manage the outcomes
- Recognize the significant HIV medication-related drug interactions, and when necessary offer alternative strategies to treatment
The curriculum offered at this activity is designed to meet the needs of Infectious Disease Physicians, Hepatologists, Gastroenterologists, Family Physicians, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists, and others involved in frontline HIV and Hepatitis patient care and treatment.
This CME activity is made possible, in part, by educational grants provided by:
AbbVie, Gilead Sciences, Janssen Therapeutics, Merck & Co., Inc, ViiV Healthcare